Liquid Biopsies – Multimedia

Understanding the integrity and quantity of your nucleic acid samples is critical for next-generation sequencing (NGS) and biobanking workflows.

Agilent sample quality metrics are available for most RNA and DNA samples used in NGS, enabling you to know the concentration, size and integrity of your nucleic acid fragments.

Since many cancers don’t have symptoms early on, they may go unnoticed until they are at an advanced stage. But that is changing, thanks to a newer, non-invasive tool.

Download this listicle to explore various biomarkers, technological advances driving biomarker research and integrative approaches in disease research.

Next-generation sequencing (NGS) is an essential tool in molecular biology laboratories for the analysis of nucleic acid samples in numerous basic, translational and clinical research settings. Download this app compendium to discover systems that can be used to analyze genomic DNA, cell-free DNA, total RNA.

For circulating cell free DNA (ccfDNA) to be used in cancer research successfully, workflow standardization is essential. Access this poster to discover tips on optimal workflow control, how to yield smaller ccfDNA fragments and the differences in quantification and qualification of ccfDNA.

Urinalysis has long been a staple of physical exams to detect and manage a number of diseases and disorders, but not cancer. What if it were that easy, though, and cancer was detected in its very earliest stages when the disease responds more favorably to treatment and improved outcomes are more likely?

Download this app note to learn more about NGS and the benefits of different approaches used for the diagnosis of diseases including circulating tumors.

Download this infographic to explore what liquid biopsies can tell us, how they compare to traditional surgical biopsies, and challenges in their development.

In cancer, rapidly emerging evidence suggests that the microbiome influences disease progression in a myriad of direct and indirect ways. In this listicle, we look at recent research developments directed towards exploring the emerging “oncomicrobiome”.